Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


First-Line Gazyva GALLIUM Success Bolsters Roche's CD20 Franchise

Executive Summary

Roche has caught investors off guard with the early announcement that its Phase III GALLIUM study of Gazyva in first-line follicular lymphoma has reached its primary endpoint of progression-free survival when pitted against the company's own standard-of-care treatment MabThera.


Related Content

Gazyva’s GALLIUM Could Be ‘Practice-Changing’ For Follicular Lymphoma
Sandoz Extrapolates Biosimilar Rituximab Data For EU Filing
New Market For Genentech's Gazyva: Follicular Lymphoma





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts